GBM AGILE Trial

Date Added
January 21st, 2020
PRO Number
Pro00089802
Researcher
David Cachia

List of Studies


Keywords
Brain Tumor, Glioblastoma
Summary

Glioblastoma adaptive, global, innovative learning environment or GBM AGILE trial is to identify effective therapies and improve survival for a type of brian cancer called glioblastoma (GBM) and to match effective therapies with adult patients with newly diagnosed or recurring glioblastoma. Eligible participants will have a 50/50 chance of taking either standard therapy medications or a medication not yet approved by the FDA called regorafenib during their standard of care treatment for GBM.

Institution
MUSC
Recruitment Contact
John Keller
843-792-2209
Kellej@musc.edu

A Randomized, Double-Blind Phase II Trial of Surgery, Radiation Therapy plus Temozolomide and Pembrolizumab with and without HSPPC-96 in Newly diagnosed Glioblastoma (GBM)

Date Added
January 8th, 2019
PRO Number
Pro00083430
Researcher
David Cachia

List of Studies


Keywords
Glioblastoma
Summary

The purpose of this study is to find out if adding a chemotherapy drug called pembrolizumab and a vaccine to standard of care treatment (temodar and radiation therapy) for glioblastoma improves survival.

Institution
MUSC
Recruitment Contact
John Keller
843-792-2209
kellej@musc.edu



-- OR --